-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Jasper Therapeutics, Lowers Price Target to $33

Benzinga·05/13/2025 15:58:37
Listen to the news
UBS analyst Trung Huynh maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the price target from $38 to $33.